Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00170885
Status:
COMPLETED
Last Update Posted:
2016-11-16
First Post:
2005-09-09
Brief Title:
Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
Multicenter Randomized Open-label Trial to Evaluate the Safety Tolerability and Efficacy of Two Regimens of Everolimus Plus Cyclosporine Microemulsion Given According to Different Blood Target Levels in de Novo Renal Transplant Recipients
Status:
COMPLETED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study in de novo renal transplant patients is to evaluate the effect on renal function of an optimized new regimen in comparison with the standard everolimus exposure plus a low-dose cyclosporine microemulsion regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None